Feasibility by indication
What makes a trial feasible — indication by indication.
Every indication has its own feasibility traps — biomarker gating, site saturation, screen fails. Each page lays out what drives go/no-go, grounded in public data and ready to run against your own protocol.
Feasibility scored across indications.
Browse indications
Start with the therapeutic area.
Each page covers what actually decides go/no-go there, which public sources carry the weight, and — where we have verified them — the counts, with a snapshot date.
Solid tumors · Phase I–II heavy
Oncology — solid tumors
Solid-tumor oncology is the most crowded area in clinical research, which makes site competition and patient overlap the dominant feasibility risks.
ClinicalTrials.gov · AACT · PubMed · +2 more
View feasibilityNSCLC · Phase II–III
Cited countsNon-small-cell lung cancer (NSCLC)
NSCLC is one of the most actively studied indications, with feasibility dominated by molecular sub-segmentation (EGFR, ALK, KRAS G12C, PD-L1 status).
ClinicalTrials.gov · AACT · PubMed · +2 more
View feasibilityBreast cancer · Phase II–III
Breast cancer
Breast-cancer feasibility hinges on receptor subtype (HR+/HER2+/triple-negative) and line of therapy.
ClinicalTrials.gov · AACT · PubMed · +2 more
View feasibilityType 2 diabetes · Phase II–III
Type 2 diabetes
Type 2 diabetes has a large prevalent population, so the feasibility risk shifts from "are there enough patients" to "can we enroll fast enough against heavy competition and tight eligibility windows." Background-therapy and HbA1c criteria do most of the cohort filtering.
ClinicalTrials.gov · AACT · PubMed · +1 more
View feasibilityAlzheimer's · Phase II–III
Alzheimer's disease
Alzheimer's feasibility is defined by hard-to-reach, biomarker-confirmed populations and notoriously slow screening.
ClinicalTrials.gov · AACT · PubMed · +2 more
View feasibilityRheumatoid arthritis · Phase II–III
Rheumatoid arthritis
Rheumatoid arthritis has a well-established trial infrastructure, so feasibility turns on eligibility layering — prior biologic exposure, disease-activity thresholds, and washout requirements — more than on patient scarcity.
ClinicalTrials.gov · AACT · PubMed · +2 more
View feasibilityWhat's underneath
Public data, cited line by line.
These pages are built from the same public sources the platform reads at run time. A figure only appears once it has been verified against a named source and stamped with a snapshot date.
See a verdict you can actually check.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.